Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
2013-002984-24Phase 2Terminated
- Sponsor
- Phenex Pharmaceuticals AG
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of px-102 in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Phenex Pharmaceuticals AG. Primary endpoint: Safety and tolerability. Started Jul 2013; status: terminated.
02
Drugs
px-102
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2013-002984-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002984-24.